|
Friday 29th November 2024 |
Text too small? |
Rua Bioscience is pleased to annouce the release of our newest dried flower product, marking another significant milestone for the company. This is the second flower product launched by Rua in New Zealand in the last six months, reflecting our ongoing efforts to grow our portfolio in our home market of Aotearoa New Zealand.
This new product has already generated significant demand ahead of its release, and Rua expects market uptake to be strong.
The New Zealand market, along with our other key markets, is still showing evidence of substantial growth. The market more than doubled in size between FY23 and FY24 which suggests greater acceptance by Doctors, Pharmacists and Patients.
[GRAPH IN ATTACHMENT]
As part of our dedication to supporting equitable access to medicines, this product will also be included in Compassionate Access Programme. This initiative reflects our commitment to redcuing barriers to access for those paitents least able to afford this medicine.
Paul Naske, CEO of Rua Bioscience says “Whilst we are focused on large export markets, this launch is testament to our connection to Aotearoa New Zealand. We’re immensly proud to bring another product to our home market”.
This significant achievement reflects Rua’s continued focus on sales and revenue growth and our commitment to delivering for the people and communities of Aotearoa New Zealand.
ENDS
No comments yet
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million
SML - Resignation of Synlait Director
FBU - Sale of Laminex Cheltenham property
CVT - Comvita Achieves Minimum Capital Raise Requirement
Devon Funds Morning Note - 04 May 2026
MEL - Meridian joins global ranks of sustainable companies
May 5th Morning Report